Opinion
‘Reform School’ for Pharmacy Benefit Managers: How Might Legislation Help Patients?
Dr. Madelaine A. Feldman writes how pending federal legislation targeting PBMs might affect patients’ access to medications and also delink drug...
News
Fed Worker Health Plans Ban Maximizers and Copay Accumulators: Why Not for the Rest of the US?
The US federal government refrains from enforcing bans on copay accumulators and maximizers for the American public, but it does ban them in its...
Opinion
Specialists Are ‘Underwater’ With Some Insurance-Preferred Biosimilars
Legislative or regulatory action is unlikely to address the current negative reimbursement situation for office-based infusion of certain...
Opinion
ERISA Health Plan Lawsuits: Why Should We Care?
Chances are high that you have patients employed by companies with self-funded health insurance plans that could be harming them both physically...
Opinion
Biosimilar Business Deals Keep Up ‘Musical Chairs’ Game of Formulary Construction
The FTC has frowned upon manufacturers owning PBMs and allowing them to construct their own formularies in the past, so why is it allowing CVS...
News
Prescription drug affordability boards: Another quick fix with unintended consequences?
Provisions included in some states’ prescription drug affordability boards may allow them to set upper payment limits for medications, potentially...
News
Insurer’s foray into AI-based ‘shared savings’ program creates ethical problems
Liability and ethical concerns arise from a recently proposed voluntary program from Blue Cross and Blue Shield of North Carolina that would...